EJP PHARMACEUTICAL ApS Financials, key figures and credit report
Gross profit -28.3 kDKK FY 2025 +14.2% vs 2024
EBIT -28.3 kDKK FY 2025 +14.2% vs 2024
Net debt - 293.6 kDKK FY 2025 +92.9% vs 2024
Quick ratio 11.0 FY 2025 -42.6 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -39.77 | -49.23 | -34.27 | -32.95 | -28.27 |
| EBIT | -39.77 | -49.23 | -34.27 | -32.95 | -28.27 |
| Other financial income | 799.65 | 111.19 | 366.82 | 363.35 | 113.45 |
| Other financial expenses | -19.76 | - 518.40 | 0.03 | -5.44 | |
| Net income from associates (fin.) | - 159.12 | - 121.21 | 194.16 | 73.82 | 153.28 |
| Pre-tax profit | 581.00 | - 577.65 | 526.74 | 404.22 | 233.02 |
| Income taxes | - 138.45 | 99.99 | -73.16 | 9.85 | -18.74 |
| Net earnings | 442.55 | - 477.66 | 453.58 | 414.07 | 214.28 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current amounts owed by group member comp. | 420.61 | 460.61 | 596.24 | 376.41 | 551.80 |
| Current deferred tax assets | 36.14 | 110.31 | 37.45 | 22.11 | 45.50 |
| Short term receivables total | 456.75 | 570.92 | 633.69 | 398.52 | 597.30 |
| Other current investments | 3 573.21 | 3 396.09 | 3 444.65 | 3 900.89 | 165.60 |
| Cash and bank deposits | 3 388.38 | 2 797.63 | 116.26 | 213.62 | 132.77 |
| Cash and cash equivalents | 6 961.59 | 6 193.72 | 3 560.91 | 4 114.52 | 298.37 |
| Balance sheet total (assets) | 7 418.35 | 6 764.64 | 4 194.60 | 4 513.04 | 895.67 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 200.00 | 200.00 | 200.00 | 200.00 | 200.00 |
| Shares repurchased | 114.40 | 3 000.00 | 122.00 | 3 828.78 | 158.80 |
| Retained earnings | 6 518.24 | 3 960.79 | 3 361.13 | -14.07 | 241.20 |
| Profit of the financial year | 442.55 | - 477.66 | 453.58 | 414.07 | 214.28 |
| Shareholders equity total | 7 275.19 | 6 683.13 | 4 136.71 | 4 428.78 | 814.28 |
| Non-current liabilities total | |||||
| Current trade creditors | 16.25 | 18.50 | 19.00 | ||
| Current owed to participating | 4.75 | 4.75 | 4.75 | 4.75 | 4.75 |
| Short-term deferred tax liabilities | 122.16 | 58.26 | 34.14 | 60.50 | 57.64 |
| Other non-interest bearing current liabilities | 0.00 | 19.00 | 19.00 | ||
| Current liabilities total | 143.16 | 81.51 | 57.89 | 84.25 | 81.39 |
| Balance sheet total (liabilities) | 7 418.35 | 6 764.64 | 4 194.60 | 4 513.04 | 895.67 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated